Appeals Court Orders DEA On MMJ Marijuana Lawsuit
9th Circuit Court of Appeals Orders DEA to Respond to MMJ's Writ of Mandamus Within 30 DaysWASHINGTON D.C. / ACCESSWIRE...
Pharmaceutical
AlzeCure Presents at Redeye Neurology Theme Event on October 11
STOCKHOLM, SWEDEN / ACCESSWIRE / October 3, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
Biotech Medics has Acquired Organic Calcium Assets
WOODLAND HILLS, CA / ACCESSWIRE / October 2, 2023 / BioTech Medics, Inc. (OTC PINK:BMCS) is pleased to announce that...
Rancho Biosciences to Showcase Cutting-Edge Data Science Services at BioTechX Europe’s Largest Pharmaceutical Development and Healthcare Event, Oct. 4-6
SAN DIEGO, CA / ACCESSWIRE / October 2, 2023 / Rancho Biosciences, the premier Data Science Services company headquartered in...
PharmaLink Launches a DSCSA Compliant Solution for Retail and Hospital Markets
LARGO, FL / ACCESSWIRE / October 2, 2023 / PharmaLink announces a comprehensive suite of Drug Supply Chain Security Act...
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early...
Clade Therapeutics Announces the Acquisition of Gadeta B.V.
Expands Clade’s pipeline and broadens its platform with:- proprietary gamma/delta (g/d) TCR universal targeting platform technology,- g/d TCR candidate integrated...
Mark Cuban Cost Plus Drug Company, PBC Joins Forces with Famlee to Revolutionize Access to Home-Based Step-Therapy Fertility Treatment, Providing an Affordable Path to Parenthood
PORTLAND, OR / ACCESSWIRE / October 2, 2023 / Famlee is revolutionizing the landscape of affordable and accessible women's fertility...
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming...
Interim results for the six months ended 30 June 2023
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa...
Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment Corporation
CAMBRIDGE, MA / ACCESSWIRE / September 29, 2023 / Moderna, Inc. (NASDAQ:MRNA) has become aware that TRC Capital Investment Corporation...
Bausch Health’s Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)
LAVAL, QC / ACCESSWIRE / September 29, 2023 / Bausch + Lomb Corporation ("Bausch + Lomb") (NYSE/TSX:BLCO), a subsidiary of...
Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
TORONTO, ON / ACCESSWIRE / September 29, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical...
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two...
TOMI Rolls Out New Innovative Disinfection Products to Support Its Expanding Customer Base
FREDERICK, Md., Sept. 29, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in...
Dyadic to Present at Industry and Investor Events in October
JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
Maravai LifeSciences Hosts 2023 Investor R&D Day
Highlights include the company’s strong foundation for growth, focus on innovation and attractive long-term outlookSAN DIEGO, Sept. 29, 2023 (GLOBE...
Outlook Therapeutics® Requests Type A Meeting With FDA
ISELIN, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA...
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase 3 clinical trials in pediatric...